FOR258D
Drug
Novartis Pharma AG
Total Payments
$13,817
Transactions
4
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1,367 | 2 | 2 |
| 2017 | $12,450 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13,817 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CFOR258D2416 | Novartis Pharma AG | $13,817 | 3 |
Ad
Manufacturing Companies
- Novartis Pharma AG $13,817
Product Information
- Type Drug
- Total Payments $13,817
- Total Doctors 3
- Transactions 4
About FOR258D
FOR258D is a drug associated with $13,817 in payments to 3 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $1,367 was paid across 2 transactions to 2 doctors.
The most common payment nature for FOR258D is "Unspecified" ($13,817, 100.0% of total).
FOR258D is associated with 1 research study, including "CFOR258D2416" ($13,817).